RT Journal Article
T1 Amino functionalized mesoporous silica nanoparticles encapsulated octahedral organoruthenium complex as an efficient platform for combatting cáncer.
A1 Martínez Carmona, Marina
A1 Qui P., Ho
A1 Morand, Jeremy
A1 García Fontecha, Ana
A1 Ortega, Enrique
A1 Luiza C.S., Erthal
A1 Ruiz-Hernandez, Eduardo
A1 Santana, Dolores M.
A1 Ruiz, José
A1 Vallet Regí, María Dulce Nombre
A1 Gun’ko, Yurii
AB In the process of synthesis of a new drug, as important as the drug itself is the formulation used, because the same compound can present a very different efficacy depending on how it is administered. In this work, we demonstrate how the antitumor capacity of a new octahedral organo-ruthenium complex, [Ru(ppy-CHO)(phen)2][PF6] is affected by its encapsulation in different types of mesoporous silica nanoparticles. The interactions between the Ru complex and the silica matrix and how these interactions are affected at two different pHs (7.4 and 5.4, mimicking physiological and endolysosomal acidic conditions, respectively) have been studied. The encapsulation has also been shown to affect the induction of apoptosis and necrosis and progression of the cell cycle compared to the free drug. The encapsulation of the Ru complex in nanoparticles functionalized with amino groups produced very high anticancer activity in cancer cells in vitro, especially against U87 glioblastoma cells, favoring cellular internalization and significantly increasing the anticancer capacity of the initial non-encapsulated Ru complex.
PB American Chemical Society
SN 0020-1669
YR 2020
FD 2020-07-06
LK https://hdl.handle.net/20.500.14352/6359
UL https://hdl.handle.net/20.500.14352/6359
LA eng
NO RESEARCHER ID M-3378-2014 (María Vallet Regí)ORCID 0000-0002-6104-4889 (María Vallet Regí)
NO Unión Europea. Horizonte 2020
NO Ministerio de Ciencia e Innovación (MICINN)/Fundación Séneca-CARM
NO FEDER
NO MultiMetDrugs network
NO Wellcome Trust/FEDER
DS Docta Complutense
RD 5 abr 2025